TAFRO Syndrome : A Disease Requiring Immediate Medical Attention
TAFRO syndrome was first described in 2010, standing for thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly. Because the lymph node histopathology of TAFRO syndrome mimics idiopathic multicentric Castleman disease (iMCD), some researchers consider TAFRO syndrome to be a subtype of iMCD. However, the clinical features of TAFRO syndrome considerably differ from those of iMCD without TAFRO. The clinical features of patients with TAFRO syndrome with or without iMCD-histopathology are similar, and these patients require an accurate diagnosis and urgent treatment. Although a histological diagnosis, including a differential diagnosis, is important, lymph node involvement in patients with TAFRO syndrome is usually modest or sometimes absent. Furthermore, a bleeding tendency due to thrombocytopenia and severe anasarca hampers performing a biopsy. Nonetheless, patients with various other disorders may manifest TAFRO syndrome-like symptoms, making the differential diagnosis in borderline cases difficult. Therefore, the establishment of precise and specific biomarkers is important.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
Internal medicine (Tokyo, Japan) - 62(2023), 1 vom: 01. Jan., Seite 27-32 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Masaki, Yasufumi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cyclosporin A |
|---|
| Anmerkungen: |
Date Completed 05.01.2023 Date Revised 03.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2169/internalmedicine.9622-22 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341215716 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341215716 | ||
| 003 | DE-627 | ||
| 005 | 20231226011253.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2169/internalmedicine.9622-22 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1137.xml |
| 035 | |a (DE-627)NLM341215716 | ||
| 035 | |a (NLM)35598998 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Masaki, Yasufumi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a TAFRO Syndrome |b A Disease Requiring Immediate Medical Attention |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.01.2023 | ||
| 500 | |a Date Revised 03.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a TAFRO syndrome was first described in 2010, standing for thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly. Because the lymph node histopathology of TAFRO syndrome mimics idiopathic multicentric Castleman disease (iMCD), some researchers consider TAFRO syndrome to be a subtype of iMCD. However, the clinical features of TAFRO syndrome considerably differ from those of iMCD without TAFRO. The clinical features of patients with TAFRO syndrome with or without iMCD-histopathology are similar, and these patients require an accurate diagnosis and urgent treatment. Although a histological diagnosis, including a differential diagnosis, is important, lymph node involvement in patients with TAFRO syndrome is usually modest or sometimes absent. Furthermore, a bleeding tendency due to thrombocytopenia and severe anasarca hampers performing a biopsy. Nonetheless, patients with various other disorders may manifest TAFRO syndrome-like symptoms, making the differential diagnosis in borderline cases difficult. Therefore, the establishment of precise and specific biomarkers is important | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a POEMS syndrome | |
| 650 | 4 | |a cyclosporin A | |
| 650 | 4 | |a idiopathic multicentric Castleman disease | |
| 650 | 4 | |a interleukin-6 | |
| 650 | 4 | |a rituximab | |
| 650 | 4 | |a tocilizumab | |
| 700 | 1 | |a Ueda, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Yanagisawa, Hiroto |e verfasserin |4 aut | |
| 700 | 1 | |a Arita, Kotaro |e verfasserin |4 aut | |
| 700 | 1 | |a Sakai, Tomoyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Yamada, Kazunori |e verfasserin |4 aut | |
| 700 | 1 | |a Mizuta, Shuichi |e verfasserin |4 aut | |
| 700 | 1 | |a Fukushima, Toshihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Takai, Kazue |e verfasserin |4 aut | |
| 700 | 1 | |a Aoki, Sadao |e verfasserin |4 aut | |
| 700 | 1 | |a Kawabata, Hiroshi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Internal medicine (Tokyo, Japan) |d 1996 |g 62(2023), 1 vom: 01. Jan., Seite 27-32 |w (DE-627)NLM012606731 |x 1349-7235 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2023 |g number:1 |g day:01 |g month:01 |g pages:27-32 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2169/internalmedicine.9622-22 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 62 |j 2023 |e 1 |b 01 |c 01 |h 27-32 | ||